---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000042"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:43:14.915590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elicio Q2 net loss $7.2M; Phase 1 data show 100% T cell response; Phase 2 enrollment Q4

## Summary
- Net loss of $7.2M ($0.64 per share) for Q2 2024; cash $3.4M at June 30, but subsequent financings raised ~$29.6M net.
- AMPLIFY-7P Phase 1 data: 100% of patients developed mKRAS-specific T-cell response; median DFS not reached at RP2D (4.9mg).
- Phase 2 randomized trial enrollment expected to complete Q4 2024; interim analysis anticipated Q1 2025.
- AMPLIFY-201 long-term follow-up to be terminated; updated data at upcoming medical meetings.

## SEC filing metadata
- accession: 0001601485-24-000042
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000042/0001601485-24-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000042/angn-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000042
- JSON: https://secwatch.observer/filing/0001601485-24-000042.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.